Studies on the Absorption of Pyridostigmine: the Application of a Spectrophotometric Method for the Determination of Pyridostigmine in Plasma by Coper, H. et al.
Coper, Deyhle and Dross: Studies on the absorption of pyridostigmine 273
Z. Klin. Chem. Klin. Biochem.
12. Jg. 1974,8.273-275
Studies on the Absorption of Pyridostigmine: the Application of a Spectrophotometric Method
for the Determination of Pyridostigmine in Plasma
By A Coper, G. Deyhle and AT. Dross
Institut für Neuropsychopharmakologie and Institut für Klinische Pharmakologie der Freien Universität Berlin
(Eingegangen am 26. November 1973/10. Januar 1974)
A method is described for the quantitative determination of pyridostigmine in blood, based on the principle of ion pair extraction.
With the aid of this method it was shown that pyridostigmine is absorbed relatively slowly and irregularly, following its oral appli-
cation. In order to achieve the same concentration in the blood of rats, the oral dose must be 50 times higher than the intraperitoneal
dose. Orientation studies on humans confirmed that the absorption is low and irregular after oral application.
Es wird ein Verfahren zur quantitativen Bestimmung von Pyridostigmin im Blut beschrieben, das auf dem Prinzip der lonenpaar-
extraktion beruht. Mit dieser Methode konnte festgestellt werden, daß Pyridostigmin nach oraler Gabe relativ gering und unregel-
mäßig resorbiert wird. Um dieselbe Konzentration im Blut der Ratte zu erreichen, wird bei oraler Gabe eine SOfach höhere Dosis
benötigt als bei intraperitonealer Verabreichung. Orientierende Versuche am Menschen haben die Ergebnisse der geringen und un-
regelmäßigen Resorption bestätigt.
The therapy of Myasthenia gravis with pyridostigmine
(Mestinon) often fails to produce the required result.
Even in favourable cases, the effective dosage varies
considerably between individuals (1). One reason for
this could be a poor and/or irregular intestinal absorp-
tion of the pyridostigmine. Little is known so far about
the uptake and distribution of this substance in the
whole organism. The present work was therefore under-
taken to determine the relationship between the py-
ridostigmine concentration in the blood and the
quantity administered orally or intraperitoneally in
experimental animals. In addition, the lethal dose was
determined for the different modes of application. A
method was also developed for the quantitative deter-
mination of pyridostigmine in plasma.
Pyridostigmine is a quaternary ammonium base, which
can be transferred to organic solvents from aqueous
solution as an ion pair with the aid of hexanitrodiphenyl-
amine (dipicrylamiiie). The ion pair can then be disso-
ciated by shaking the organic phase with diluted hy-
drochloric acid, whereby the pyridostigmine is trans-
ferred to the aqueous phase, being finally purified, iso-
lated and identified by chromatography (3,4).
This rather laborious and time consuming procedure
can be avoided by following the acid treatment with
an ion pair extraction of the amine with I3. The result-
ing I9 -complex in the organic phase possesses two
typical absorption maxima at 365 and 293 run, which
can be measured directly in a spectrophotometer (5).
The determination procedure can be summarized as
follows:
1. Pyridostigmine is mixed with dipicrylamine in a
neutral buffer. The resulting stable ion pair is ex-
tracted with dichloromethane.
2. The dichloromethane phase is evaporated to dryness,
the ion pair cleaved with HC1 and the dipicrylamine
removed by extraction again with dichloromethane.
3. The iodine complex of pyridostigmine is formed
with the aid of KI3. This complex is extracted with
dichloromethane, and determined spectrophoto-
metrically by measuring the absorbance at 293, 329
and 365 run.
Materials and Methods
Reagents
1. Mestinon (solid pure substance) from Hoffmann-La Roche1)
2. Dipicrylamine (moistened with an equal part of water) p. a.
Merck 3089
3. Sodium dihydrogen phosphate 1-hydrate p. a. (NaH2PO4 ·
H20) Merck 6346
4. Sodium hydroxide flakes, reinst, p. a. Merck 6498
5. Iodine doubly sublimed p. a. Merck 4761
6. Potassium iodide neutral p. a. Merck 5043
7. Sodium sulphate, anhydrous p. a. Merck 6649
8. Dichloromethane p. a. Merck 6050, distilled
9. Heparin (solid substance) Hoffmann-La Roche1)
l ) Mestinon and heparin were generous gifts from Hoffmann-
La Roche.
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Solutions
1. Dipicryluminc solution 10 inmol/l: 440 ing dipicrylaminc
arc dissolved In 8 ml l m ο I/1 NuOH; 20 mi 0.5 rtiol/1
NuHaPCXj arc added and the volume is adjusted to
50.0 ml with distilled water, The pil of this solution is
7.0-7.15,
2. Iodine solution.
15.7 g iodine and 20.0 g Kl are dissolved in 100.0 ml
distilled water and shaken mechanically for 40 in in. This
solution is stable indefinitely at 4° C (2). The stock solution
is diluted 1:10 with water. This solution is stable for about
3 weeks.
Exper imental an imals
The experimental animals were female albino rats, wistar strain,
from the Hoffmann animal breeding fnrm, Berlin. They weighed
180-220 g, and received water and Altrotnin R 10 dry food
ad libitum.
D e t e r m i n a t i o n of pyr idos t igminc
Rats were decapitated and their blood collected in centrifuge
tubes containing a small amount of hcpartn (solid substance).
After centrifugatlon at 3,000 rpm, 3 nil of the supernatant
plasma were used for the determination.
A nal) · ficttl tncihod
1. 3 ml plasma are mixed with 1 ml dlpicrylamine solution
(10 wwol/l), followed by 25 ml dichloromethanc, and
the mixture; in a glass stoppered centrifuge tube, is shaken
vertically on a mechanical shaker for 30 min at 20 rpm.
After 10 min centrifugal ion at 1,500 rpm, 20 ml of the
dichloromethane phase arc removed. The most favourable
extraction of the pyridostigminc complex from the plasma
into the organic phase occurs at pH 7.2. The extraction
yield from rat plasma or whole blood is 93%, as determined
in serial experiments in which pure pyridostigminc was
determined with or without prior extraction. Variations
in the ratio of volumes of dipicrylaminc solution and di-
chloromcthnne, in the concentration and quantity of
dipicrylnminc, or in the shaking time offered no advantages.
The results were not improved by deprotcinization of the
rat blood, by acid precipitation, or boiling.
2. The dichloromethnne phase (20 ml), in a ground glass
centrifuge tube, is evaporated to dryness in a stream of air.
The residue can be stored overnight in the refrigerator
without loss. It is dissolved in 0.5 ml 0.05 mol/1 HO and
the residual dipicrylumine, which is still present at this
stage, is removed by washing first with 6 ml, then with
3 ml dichloromethnne.
3. The nquuous phase is mixed with 20 μΐ Kl3 solution plus
3 ml dichloromoihane, then shaken for 10 min at 40 rpm.
After centrifugal ion to separate the phases, the organic
phase is transferred to α glass stoppered tube containing
10 mg anhydrous sodium sulphate. The solution is con-
trifuged and its absorbancc measured nt 293, 329 and 365 nm
against dichloromethanc. The quantity of pyridostigmlne
can be dtMcrmined from the difference in the absorbancc at
293 and 329, or 293 and 365 nm (Fig. lb), using a calibration
curve prepared with pure material in 3 ml of plasma from an
untreated animal. In the concentration range encountered in
the animal experiments and in humans, i, e, 0.5-5 Mg/3 ml
plasma, the individual calibration values show a scatter of
10-20% around the average.
Preliminary investigation of the method showed that light causes
α linear decrease in the extinction after the addition of
the Klj solution. The spectrum also shows qualitative and
quantitative changes (Fig. l, u and b). After shaking, all the
samples must therefore be stored in the dark.
Choline occurs naturally in plasma and it is precipitated from
aqueous solution with la* (2), but it does not interfere because,
unlike pyrvdostigmine, it cannot be extracted as its I£ complex
with dichloromethane or chloroform (5). Erroneous results
can be obtained, however, when other pharmaceutical'com*
pounds are administered at the same time (unpublished results).
Under the above conditions, the lower limit for the determina-
tion of pyridostigmtne is 0.3 Mg/3 ml plasma.
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Fig. 1. Alteration with time of the UV absorption of the iodine
complex of pyridostigmine with KI3 in dichloromethanc,
a) in the light b) in the dark.
Application of pyridostigminc
In the first series of experiments, the relationship between the
dose and the plasma concentration was determined at an
arbitrarily fixed time after application. The pyridostigmine was
administered in 1 ml aqueous solution per 100 g animal body
weight. The rats were killed 5 min after the intraperitoneal
injection of 1, 2, 3 and 4 mg/kg, and 15 min after the oral
application of 50, 70, 90 and 110 mg/kg.
In the second series of experiments, the animals received 2 mg
pyridostigmine per kg body weight L p. (1 ml aqueous solution/
100 g). Decapitation was 5,10,15, 20, 30 and 40 min after the
application. For comparison, another group of rats received
50 mg pyridostigminc per kg orally, again in 1 ml per 100 g.
Those animals were killed 30, 60,120,180 and 240 min after
the application.
Results
The LDso for pyridostigmine after i. p. injection in rats
is 3 mg/kg. A concentration range of 1-10 mg/kg was
tested on 5 groups, each containing 6 rats, and the result
was calculated according to Kfirber (6). After oral appli-
cation, however, the LDSO is 115 mg/kg (7 values, each
determined on 6 rats for the range 10-180 mg/kg), with
considerable scatter. This value alone indicates that the
intestinal absorption is low; this is confirmed by expe-
riments in which the pyridostigmine concentration in
the plasma was determined after oral and i. p. appli-
cation. Figure 2 shows that after the i. p. application
of 1-4 mg/kg, the concentration of pyridostigmine in
the plasma shows a relatively steep and linear increase.
After oral dosage, however, the ratio, dose : plasma con-
centration, is much flatter. Thus, for the same plasma
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concentration, the dose ratio for intraperitoneal: oral
is about 1:55.
Pyridostigmine appears rapidly in the blood and reaches
a maximum concentration in the plasma 5 min after
s
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Fig. 2. Dose versus plasma concentration of pyridostigmine for
intraperitoneal (o ο 5 min after 1—4 mg/kg) and oral
(o ο 15 min after 50-110 mg/kg) application. Each
point represents the average (± s) from 4-7 animals.
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Fig. 3. Comparison of the plasma concentrations of pyridostig-
mine in the rat after intraperitoneal (o— - — o, 2 mg/kg)
and oral (· - · 50 mg/kg) application. Each point re-
presents the average (± s) from 10—11 animals.
i. p. application (Fig. 3). Absorption from the peritoneal
cavity is therefore very rapid. For the concentration
range used in these experiments, the half life of the
elimination, starting from the maximum, is 28 min. In
contrast, it takes 30 min to attain the maximal concen-
tration after oral application. At this time, the ab-
sorption is probably still incomplete, for, as shown in
Figure 3, the subsequent elimination occurs much more
slowly. Plasma pyridostigmine concentrations above
2 μ§/3 ml give rise to easily recognizable muscular con-
vulsions, shivering and chromodacryorrhea, etc. After
an i. p. application of 2 mg/kg, these symptoms become
apparent within the first 5 min, and they have largely
died away after 15—20 min. After 50 mg/kg orally,
however, these symptoms do not appear for 20—30 min,
after which they continue for further 30 min. Investi-
gations on humans principally confirmed that the ab-
sorption is low and irregular after oral application. This
is demonstrated in Figure 4 for four patients who re-
ceived 120 mg pyridostigmine in the form of Mestinon
dragees. Since the determination method is not sensitive
below 0.5 μg/3 ml and the scatter in this part of the
calibration curve is greater than 20%, it is not known
if absorption occured during the first hour in patients
S. L. and E. J.
A detailed study of the relationship between the serum
concentration of pyridostigmine and its therapeutic
effect, or its possible toxic action will be published
elsewhere.
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Fig. 4. Behaviour of the pyridostigmine concentration in the
serum of patients after the oral application of 120 mg
Mestinon.
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